Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
PMID:

Abstract

BACKGROUND: Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown.

Authors

  • Devyani Deshpande
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Jotam G Pasipanodya
    Center for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
  • Stellah G Mpagama
    Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
  • Paula Bendet
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Shashikant Srivastava
    Center for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA.
  • Thearith Koeuth
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Pooi S Lee
    Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.
  • Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Schenectady, New York.
  • Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Schenectady, New York.
  • Guy Thwaites
    Oxford University Clinical Research Unit, Ho Chi Minh City and Hanoi, Vietnam.
  • Scott K Heysell
    Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
  • Tawanda Gumbo
    The Cardiac Clinic, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa; Center for Infectious Diseases Research & Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.